Estrogen, estrogen plus progestin therapy, and risk of breast cancer

Graham A. Colditz, James Ingle, Richard Santen, Kent Osborne, Donald McDonnell, C. Kent Osborne, Carlos Arteaga

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Epidemiologic evidence relating use of postmenopausal hormones to risk of breast cancer by nature relies on trends in prescribing practices. Data on the adverse effect of combination estrogen plus progestin used for long durations has only become available over the past decade. Evidence is reviewed relating estrogen alone and estrogen plus progestin to increased risk of breast cancer. Whereas current evidence indicates that longer duration of use increases risk of invasive breast cancer regardless of formulation, the rate of increase in risk is greater for combination estrogen plus progestin therapy. Although data are limited, continuous combined therapy and sequential therapy seem to have comparable impact on breast cancer risk. Combination therapy is more strongly related to lobular breast cancer than is estrogen alone. Unresolved issues remain about dose of estrogen and progestin in relation to risk, and about identification of women for whom short-term use to relieve menopausal symptoms may be safe and effective.

Original languageEnglish (US)
JournalClinical Cancer Research
Volume11
Issue number2 II
StatePublished - Jan 15 2005
Externally publishedYes

Fingerprint

Progestins
Estrogens
Breast Neoplasms
Therapeutics
Estrogen Replacement Therapy
Hormones

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Colditz, G. A., Ingle, J., Santen, R., Osborne, K., McDonnell, D., Osborne, C. K., & Arteaga, C. (2005). Estrogen, estrogen plus progestin therapy, and risk of breast cancer. Clinical Cancer Research, 11(2 II).

Estrogen, estrogen plus progestin therapy, and risk of breast cancer. / Colditz, Graham A.; Ingle, James; Santen, Richard; Osborne, Kent; McDonnell, Donald; Osborne, C. Kent; Arteaga, Carlos.

In: Clinical Cancer Research, Vol. 11, No. 2 II, 15.01.2005.

Research output: Contribution to journalArticle

Colditz, GA, Ingle, J, Santen, R, Osborne, K, McDonnell, D, Osborne, CK & Arteaga, C 2005, 'Estrogen, estrogen plus progestin therapy, and risk of breast cancer', Clinical Cancer Research, vol. 11, no. 2 II.
Colditz GA, Ingle J, Santen R, Osborne K, McDonnell D, Osborne CK et al. Estrogen, estrogen plus progestin therapy, and risk of breast cancer. Clinical Cancer Research. 2005 Jan 15;11(2 II).
Colditz, Graham A. ; Ingle, James ; Santen, Richard ; Osborne, Kent ; McDonnell, Donald ; Osborne, C. Kent ; Arteaga, Carlos. / Estrogen, estrogen plus progestin therapy, and risk of breast cancer. In: Clinical Cancer Research. 2005 ; Vol. 11, No. 2 II.
@article{062942a513c84a73b9e5bbdbba6c3350,
title = "Estrogen, estrogen plus progestin therapy, and risk of breast cancer",
abstract = "Epidemiologic evidence relating use of postmenopausal hormones to risk of breast cancer by nature relies on trends in prescribing practices. Data on the adverse effect of combination estrogen plus progestin used for long durations has only become available over the past decade. Evidence is reviewed relating estrogen alone and estrogen plus progestin to increased risk of breast cancer. Whereas current evidence indicates that longer duration of use increases risk of invasive breast cancer regardless of formulation, the rate of increase in risk is greater for combination estrogen plus progestin therapy. Although data are limited, continuous combined therapy and sequential therapy seem to have comparable impact on breast cancer risk. Combination therapy is more strongly related to lobular breast cancer than is estrogen alone. Unresolved issues remain about dose of estrogen and progestin in relation to risk, and about identification of women for whom short-term use to relieve menopausal symptoms may be safe and effective.",
author = "Colditz, {Graham A.} and James Ingle and Richard Santen and Kent Osborne and Donald McDonnell and Osborne, {C. Kent} and Carlos Arteaga",
year = "2005",
month = "1",
day = "15",
language = "English (US)",
volume = "11",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "2 II",

}

TY - JOUR

T1 - Estrogen, estrogen plus progestin therapy, and risk of breast cancer

AU - Colditz, Graham A.

AU - Ingle, James

AU - Santen, Richard

AU - Osborne, Kent

AU - McDonnell, Donald

AU - Osborne, C. Kent

AU - Arteaga, Carlos

PY - 2005/1/15

Y1 - 2005/1/15

N2 - Epidemiologic evidence relating use of postmenopausal hormones to risk of breast cancer by nature relies on trends in prescribing practices. Data on the adverse effect of combination estrogen plus progestin used for long durations has only become available over the past decade. Evidence is reviewed relating estrogen alone and estrogen plus progestin to increased risk of breast cancer. Whereas current evidence indicates that longer duration of use increases risk of invasive breast cancer regardless of formulation, the rate of increase in risk is greater for combination estrogen plus progestin therapy. Although data are limited, continuous combined therapy and sequential therapy seem to have comparable impact on breast cancer risk. Combination therapy is more strongly related to lobular breast cancer than is estrogen alone. Unresolved issues remain about dose of estrogen and progestin in relation to risk, and about identification of women for whom short-term use to relieve menopausal symptoms may be safe and effective.

AB - Epidemiologic evidence relating use of postmenopausal hormones to risk of breast cancer by nature relies on trends in prescribing practices. Data on the adverse effect of combination estrogen plus progestin used for long durations has only become available over the past decade. Evidence is reviewed relating estrogen alone and estrogen plus progestin to increased risk of breast cancer. Whereas current evidence indicates that longer duration of use increases risk of invasive breast cancer regardless of formulation, the rate of increase in risk is greater for combination estrogen plus progestin therapy. Although data are limited, continuous combined therapy and sequential therapy seem to have comparable impact on breast cancer risk. Combination therapy is more strongly related to lobular breast cancer than is estrogen alone. Unresolved issues remain about dose of estrogen and progestin in relation to risk, and about identification of women for whom short-term use to relieve menopausal symptoms may be safe and effective.

UR - http://www.scopus.com/inward/record.url?scp=12144252426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12144252426&partnerID=8YFLogxK

M3 - Article

C2 - 15701886

AN - SCOPUS:12144252426

VL - 11

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 2 II

ER -